ESMO rare cancers

Trials for Rare Cancers Are More Successful than those for Common Cancers.

Pub Date : 2026-09-01 DOI: 10.1016/j.esmorc.2026.100523 Varun Kasibhatla, Alejandro A Schäffer, Sumeet Patiyal, Tian-Gen Chang, Padma Sheila Rajagopal, Eytan Ruppin

Molecular profiling of sacral chordomas through methylation, spatial transcriptomics and multiplexed immunofluorescence.

Pub Date : 2026-03-01 DOI: 10.1016/j.esmorc.2025.100115 Y H Foong, G Jour, G Sinha, J Benhamida, N Aleynick, H Le, A Zellmer, Y Li, T Hollmann, M Gounder, R Sardana, C Saoud, M Vaynrub, P Boland, R Vanguri, M Hameed

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

Pub Date : 2026-03-01 DOI: 10.1016/j.esmorc.2026.100129 K Demanelis, J Leix, M A Burgess, B A Nacev